| Annual · values | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| EBITDA Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Net Margin | — | — | — | — | — | — | — | — | — | — | — | — |
| Current Ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.12 | 41.83 | 66.40 | 2.52 | 2.16 | 7.69 | 0.03 |
| Quick Ratio | 9.33 | 33.09 | 19.19 | 7.61 | 23.98 | 21.12 | 41.83 | 66.40 | 2.52 | 2.16 | 7.69 | 0.03 |
| Debt / Equity | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE | -56.28% | -12.49% | -24.65% | -47.39% | -27.24% | -16.16% | -9.30% | -7.41% | -152.83% | -183.17% | -268.24% | 98.90% |
| ROA | -50.25% | -12.11% | -23.31% | -40.86% | -26.10% | -15.40% | -9.07% | -7.30% | -93.02% | -101.35% | -151.59% | -719.13% |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book Value / Share | 5.67 | 8.07 | 3.69 | 1.89 | 2.62 | 3.37 | 3.85 | 5.17 | 0.52 | 0.49 | 1.37 | -5.28 |
Viking Therapeutics is a clinical-stage biopharmaceutical company focused on developing innovative therapies for metabolic and endocrine disorders. The company's lead program, VK2735, is a dual GLP-1/GIP receptor agonist currently in Phase 3 clinical trials for obesity, with formulations in both subcutaneous injectable and oral tablet forms. VK2809, another key candidate, targets lipid and metabolic disorders including non-alcoholic steatohepatitis and fatty liver disease. The company also develops VK0214 for the rare disease X-linked adrenoleukodystrophy and is advancing a program of dual amylin and calcitonin receptor agonists for obesity and related metabolic conditions. Headquartered in San Diego, California, Viking leverages its expertise in metabolic biology to address significant unmet medical needs in obesity and metabolic disease management.